Anne-Line Couillerot-Peyrondet1, Cléa Sambuc2, Yoël Sainsaulieu3, Cécile Couchoud4, Isabelle Bongiovanni-Delarozière2. 1. Service évaluation économique et santé publique. Haute Autorité de Santé, 5 avenue du Stade de France, 93218, Saint-Denis La Plaine Cedex, France. al.couillerot@has-sante.fr. 2. Service évaluation économique et santé publique. Haute Autorité de Santé, 5 avenue du Stade de France, 93218, Saint-Denis La Plaine Cedex, France. 3. Pôle Organisation et Financement des Activités de Soins. Agence de la biomédecine, Saint-Denis La Plaine, France. 4. REIN registry. Agence de la biomédecine, Saint-Denis La Plaine, France.
Abstract
OBJECTIVES: In the current pressured economic context, and to continue to treat the growing number of patients with high-quality standards, the first step is to have a better understanding of the costs related to end-stage renal disease (ESRD) treatment according to various renal replacement therapy, age, diabetes status, and clinical events. METHODS: In order to estimate the direct costs of all adult ESRD patients, according to (RRT) modality, patient condition, and clinical events, data from the French national health insurance funds were used. RESULTS: The mean monthly costs for the 47,862 stable prevalent patients (73 % of the population) varied substantially according to treatment modality (from 7300€ for in-center hemodialysis to 1100€ for a functioning renal graft) and to clinical event (8300€ for the first month of dialysis, 11,000€ for the last month before death, 22,800€ for the first month after renal transplantation). Mean monthly costs varied according to diabetic status and to age to a lesser extent. CONCLUSIONS: These results demonstrate, for the first time in France and in Europe, the importance of a dynamic view of renal care and the bias likely when comparing treatments in cross-sectional studies.
OBJECTIVES: In the current pressured economic context, and to continue to treat the growing number of patients with high-quality standards, the first step is to have a better understanding of the costs related to end-stage renal disease (ESRD) treatment according to various renal replacement therapy, age, diabetes status, and clinical events. METHODS: In order to estimate the direct costs of all adult ESRDpatients, according to (RRT) modality, patient condition, and clinical events, data from the French national health insurance funds were used. RESULTS: The mean monthly costs for the 47,862 stable prevalent patients (73 % of the population) varied substantially according to treatment modality (from 7300€ for in-center hemodialysis to 1100€ for a functioning renal graft) and to clinical event (8300€ for the first month of dialysis, 11,000€ for the last month before death, 22,800€ for the first month after renal transplantation). Mean monthly costs varied according to diabetic status and to age to a lesser extent. CONCLUSIONS: These results demonstrate, for the first time in France and in Europe, the importance of a dynamic view of renal care and the bias likely when comparing treatments in cross-sectional studies.
Authors: Sigrid M Mohnen; Manon J M van Oosten; Jeanine Los; Martijn J H Leegte; Kitty J Jager; Marc H Hemmelder; Susan J J Logtenberg; Vianda S Stel; Leona Hakkaart-van Roijen; G Ardine de Wit Journal: PLoS One Date: 2019-08-15 Impact factor: 3.240
Authors: Manon J M van Oosten; Susan J J Logtenberg; Martijn J H Leegte; Henk J G Bilo; Sigrid M Mohnen; Leona Hakkaart-van Roijen; Marc H Hemmelder; G Ardine de Wit; Kitty J Jager; Vianda S Stel Journal: Nephrol Dial Transplant Date: 2020-12-04 Impact factor: 5.992
Authors: Edouard L Fu; Marie Evans; Juan-Jesus Carrero; Hein Putter; Catherine M Clase; Fergus J Caskey; Maciej Szymczak; Claudia Torino; Nicholas C Chesnaye; Kitty J Jager; Christoph Wanner; Friedo W Dekker; Merel van Diepen Journal: BMJ Date: 2021-11-29
Authors: Bernard Canaud; Jeroen P Kooman; Nicholas M Selby; Maarten Taal; Andreas Maierhofer; Pascal Kopperschmidt; Susan Francis; Allan Collins; Peter Kotanko Journal: World J Nephrol Date: 2022-03-25
Authors: Sarah Elshahat; Paul Cockwell; Alexander P Maxwell; Matthew Griffin; Timothy O'Brien; Ciaran O'Neill Journal: PLoS One Date: 2020-03-24 Impact factor: 3.240